Paper
Journal of Medical Marketing (2003) 3, 239–244; doi:10.1057/palgrave.jmm.5040126
EU enlargement, the Bolar exemption and parallel imports: The consequences for market exclusivity
Nigel Stoate
Taylor Wessing, Carmelite, 50 Victoria Embankment, London, EC4Y ODX, UK, Tel: +44 (0)20 7300 7000, Email: nstoate@taylorwessing.com
Revised 7 March 2003.
Abstract
The global environment in which pharmaceutical and other medical companies operate is affected by the matter of EU enlargement both directly and indirectly. Key considerations arising are the Bolar Exemption and parallel importing. This paper looks at the current state of play regarding the 13 nations in line to join the EU, provides an overview of the Bolar Exemption and its implications for the medical industry and considers the effect that EU enlargement will have on parallel importing.
Keywords:
EU enlargement, accession, experimental use, bolar exemption, parallel imports
